1
|
Kerru N, Singh-Pillay A, Awolade P, Singh P. Current anti-diabetic agents and their molecular targets: A review. Eur J Med Chem 2018; 152:436-488. [PMID: 29751237 DOI: 10.1016/j.ejmech.2018.04.061] [Citation(s) in RCA: 185] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Revised: 04/17/2018] [Accepted: 04/30/2018] [Indexed: 12/22/2022]
Abstract
Diabetes mellitus is a medical condition characterized by the body's loss of control over blood sugar. The frequency of diagnosed cases and consequential increases in medical costs makes it a rapidly growing chronic disease that threatens human health worldwide. In addition, its unnerving statistical projections are perilous to both the economy of the nation and man's life expectancy. Type-I and type-II diabetes are the two clinical forms of diabetes mellitus. Type-II diabetes mellitus (T2DM) is illustrated by the abnormality of glucose homeostasis in the body, resulting in hyperglycemia. Although significant research attention has been devoted to the development of diabetes regimens, which demonstrates success in lowering blood glucose levels, their efficacies are unsustainable due to undesirable side effects such as weight gain and hypoglycemia. Over the years, heterocyclic scaffolds have been the basis of anti-diabetic chemotherapies; hence, in this review we consolidate the use of bioactive scaffolds, which have been evaluated for their biological response as inhibitors against their respective anti-diabetic molecular targets over the past five years (2012-2017). Our investigation reveals a diverse target set which includes; protein tyrosine phosphatase 1 B (PTP1B), dipeptidly peptidase-4 (DPP-4), free fatty acid receptors 1 (FFAR1), G protein-coupled receptors (GPCR), peroxisome proliferator activated receptor-γ (PPARγ), sodium glucose co-transporter-2 (SGLT2), α-glucosidase, aldose reductase, glycogen phosphorylase (GP), fructose-1,6-bisphosphatase (FBPase), glucagon receptor (GCGr) and phosphoenolpyruvate carboxykinase (PEPCK). This review offers a medium on which future drug design and development toward diabetes management may be modelled (i.e. optimization via structural derivatization), as many of the drug candidates highlighted show promise as an effective anti-diabetic chemotherapy.
Collapse
Affiliation(s)
- Nagaraju Kerru
- School of Chemistry and Physics, University of KwaZulu-Natal, P/Bag X54001, Westville, Durban, South Africa
| | - Ashona Singh-Pillay
- School of Chemistry and Physics, University of KwaZulu-Natal, P/Bag X54001, Westville, Durban, South Africa.
| | - Paul Awolade
- School of Chemistry and Physics, University of KwaZulu-Natal, P/Bag X54001, Westville, Durban, South Africa
| | - Parvesh Singh
- School of Chemistry and Physics, University of KwaZulu-Natal, P/Bag X54001, Westville, Durban, South Africa.
| |
Collapse
|
2
|
Khasanov AF, Kopchuk DS, Kim GA, Slepukhin PA, Kovalev IS, Santra S, Zyryanov GV, Majee A, Chupakhin ON, Charushin VN. Pot, Atom, Step Economic (PASE) Approach towards (Aza
)-2,2′-Bipyridines: Synthesis and Photophysical Studies. ChemistrySelect 2018. [DOI: 10.1002/slct.201702350] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Albert F. Khasanov
- Department Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute; Ural Federal University; 19 Mira Str. Yekaterinburg, K-2 620002 Russian Federation
| | - Dmitry S. Kopchuk
- Department Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute; Ural Federal University; 19 Mira Str. Yekaterinburg, K-2 620002 Russian Federation
- I. Ya. Postovskiy Institute of Organic Synthesis; Ural Division of the Russian Academy of Sciences; 22 S. Kovalevskoy Str. Yekaterinburg 620219 Russian Federation
| | - Grigory A. Kim
- Department Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute; Ural Federal University; 19 Mira Str. Yekaterinburg, K-2 620002 Russian Federation
- I. Ya. Postovskiy Institute of Organic Synthesis; Ural Division of the Russian Academy of Sciences; 22 S. Kovalevskoy Str. Yekaterinburg 620219 Russian Federation
| | - Pavel A. Slepukhin
- Department Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute; Ural Federal University; 19 Mira Str. Yekaterinburg, K-2 620002 Russian Federation
- I. Ya. Postovskiy Institute of Organic Synthesis; Ural Division of the Russian Academy of Sciences; 22 S. Kovalevskoy Str. Yekaterinburg 620219 Russian Federation
| | - Igor S. Kovalev
- Department Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute; Ural Federal University; 19 Mira Str. Yekaterinburg, K-2 620002 Russian Federation
| | - Sougata Santra
- Department Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute; Ural Federal University; 19 Mira Str. Yekaterinburg, K-2 620002 Russian Federation
| | - Grigory V. Zyryanov
- Department Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute; Ural Federal University; 19 Mira Str. Yekaterinburg, K-2 620002 Russian Federation
- I. Ya. Postovskiy Institute of Organic Synthesis; Ural Division of the Russian Academy of Sciences; 22 S. Kovalevskoy Str. Yekaterinburg 620219 Russian Federation
| | - Adinath Majee
- Department of Chemistry; Visva-Bharati (A Central University); Santiniketan- 731235 India
| | - Oleg N. Chupakhin
- Department Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute; Ural Federal University; 19 Mira Str. Yekaterinburg, K-2 620002 Russian Federation
- I. Ya. Postovskiy Institute of Organic Synthesis; Ural Division of the Russian Academy of Sciences; 22 S. Kovalevskoy Str. Yekaterinburg 620219 Russian Federation
| | - Valery N. Charushin
- Department Department of Organic and Biomolecular Chemistry, Chemical Engineering Institute; Ural Federal University; 19 Mira Str. Yekaterinburg, K-2 620002 Russian Federation
- I. Ya. Postovskiy Institute of Organic Synthesis; Ural Division of the Russian Academy of Sciences; 22 S. Kovalevskoy Str. Yekaterinburg 620219 Russian Federation
| |
Collapse
|
3
|
Synthesis of 2,4-diamino-6-aryl-5-pyrimidinecarbonitrile promoted by amino-functionalized CoFe2O4@SiO2 nanoparticles under conventional heating, microwave and ultrasound irradiations. ACTA ACUST UNITED AC 2017. [DOI: 10.1515/znb-2017-0114] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Abstract
Amino-functionalized CoFe2O4@SiO2 nanoparticles have been used as an efficient catalyst for the preparation of 2,4-diamino-6-arylpyrimidine-5-carbonitrile derivatives by the one-pot reaction of aromatic aldehydes, malononitrile, and guanidine hydrochloride under conventional heating, microwave, and ultrasound irradiations. This method provides several advantages including mild reaction conditions, the reusability of the catalyst and low catalyst loading, and the use of microwave and ultrasonic irradiation as a valuable and powerful tool.
Collapse
|
4
|
Moodaley R, Smith DM, Tough IR, Schindler M, Cox HM. Agonism of free fatty acid receptors 1 and 4 generates peptide YY-mediated inhibitory responses in mouse colon. Br J Pharmacol 2017; 174:4508-4522. [PMID: 28971469 DOI: 10.1111/bph.14054] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Revised: 09/16/2017] [Accepted: 09/20/2017] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND AND PURPOSE Free fatty acid receptors FFA1 and FFA4 are located on enteroendocrine L cells with the highest gastrointestinal (GI) expression in descending colon. Their activation causes the release of glucagon-like peptide 1 and peptide YY (PYY) from L cells. Additionally, FFA1 agonism releases insulin from pancreatic β cells. As these receptors are modulators of nutrient-stimulated glucose regulation, the aim of this study was to compare the pharmacology of commercially available agonists (TUG424, TUG891, GW9508) with proven selective agonists (JTT, TAK-875, AZ423, Metabolex-36) in mice. EXPERIMENTAL APPROACH Mouse mucosa was mounted in Ussing chambers, voltage-clamped and the resultant short-circuit current (Isc ) was recorded continuously. Pretreatments included antagonists of FFA1, Y1 or Y2 receptors. Glucose sensitivity was investigated by mannitol replacement apically, and colonic and upper GI transit was assessed in vitro and in vivo. KEY RESULTS FFA1 and FFA4 agonism required glucose and reduced Isc in a PYY-Y1 receptor-dependent manner. The novel compounds were more potent than GW9508. The FFA1 antagonists (GW1100 and ANT825) blocked FFA1 activity only and revealed FFA1 tonic activity. The FFA4 agonist, Metabolex-36, slowed colonic transit in vitro but increased small intestinal transit in vivo. CONCLUSIONS AND IMPLICATIONS The selective FFA1 and FFA4 agonists were more potent at reducing Isc than GW9508, a dual FFA1 and FFA4 agonist. A paracrine epithelial mechanism involving PYY-stimulated Y1 receptors mediated their responses, which were glucose sensitive, potentially limiting hypoglycaemia. ANT825 revealed tonic activity and the possibility of endogenous FFA1 ligands causing PYY release. Finally, FFA4 agonism induced regional differences in transit.
Collapse
Affiliation(s)
- Runisha Moodaley
- Wolfson Centre for Age-Related Diseases, King's College London, London, UK
| | - David M Smith
- Discovery Sciences, Innovative Medicines & Early Development Biotech Unit, AstraZeneca, Cambridge, UK
| | - Iain R Tough
- Wolfson Centre for Age-Related Diseases, King's College London, London, UK
| | - Marcus Schindler
- AstraZeneca Mölndal, Innovative Medicines & Early Development, Cardiovascular & Metabolic Diseases iMed, Mölndal, Sweden
| | - Helen M Cox
- Wolfson Centre for Age-Related Diseases, King's College London, London, UK
| |
Collapse
|
5
|
Kristinsson H, Sargsyan E, Manell H, Smith DM, Göpel SO, Bergsten P. Basal hypersecretion of glucagon and insulin from palmitate-exposed human islets depends on FFAR1 but not decreased somatostatin secretion. Sci Rep 2017; 7:4657. [PMID: 28680093 PMCID: PMC5498543 DOI: 10.1038/s41598-017-04730-5] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Accepted: 06/01/2017] [Indexed: 12/19/2022] Open
Abstract
In obesity fasting levels of both glucagon and insulin are elevated. In these subjects fasting levels of the free fatty acid palmitate are raised. We have demonstrated that palmitate enhances glucose-stimulated insulin secretion from isolated human islets via free fatty acid receptor 1 (FFAR1/GPR40). Since FFAR1 is also present on glucagon-secreting alpha-cells, we hypothesized that palmitate simultaneously stimulates secretion of glucagon and insulin at fasting glucose concentrations. In addition, we hypothesized that concomitant hypersecretion of glucagon and insulin was also contributed by reduced somatostatin secretion. We found basal glucagon, insulin and somatostatin secretion and respiration from human islets, to be enhanced during palmitate treatment at normoglycemia. Secretion of all hormones and mitochondrial respiration were lowered when FFAR1 or fatty acid β-oxidation was inhibited. The findings were confirmed in the human beta-cell line EndoC-βH1. We conclude that fatty acids enhance both glucagon and insulin secretion at fasting glucose concentrations and that FFAR1 and enhanced mitochondrial metabolism but not lowered somatostatin secretion are crucial in this effect. The ability of chronically elevated palmitate levels to simultaneously increase basal secretion of glucagon and insulin positions elevated levels of fatty acids as potential triggering factors for the development of obesity and impaired glucose control.
Collapse
Affiliation(s)
- H Kristinsson
- Department of Medical Cell Biology, Uppsala University, BMC, Husargatan 3, Uppsala, Sweden.
| | - E Sargsyan
- Department of Medical Cell Biology, Uppsala University, BMC, Husargatan 3, Uppsala, Sweden
| | - H Manell
- Department of Medical Cell Biology, Uppsala University, BMC, Husargatan 3, Uppsala, Sweden
| | - D M Smith
- Discovery Sciences, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, UK
| | - S O Göpel
- AstraZeneca R&D Gothenburg, CVMD Bioscience, Gothenburg, Sweden
| | - P Bergsten
- Department of Medical Cell Biology, Uppsala University, BMC, Husargatan 3, Uppsala, Sweden
| |
Collapse
|
6
|
Li Z, Xu X, Huang W, Qian H. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges. Med Res Rev 2017; 38:381-425. [DOI: 10.1002/med.21441] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 01/23/2017] [Accepted: 02/14/2017] [Indexed: 12/19/2022]
Affiliation(s)
- Zheng Li
- Center of Drug Discovery, State Key Laboratory of Natural Medicines; China Pharmaceutical University; 24 Tongjiaxiang Nanjing 210009 P.R. China
| | - Xue Xu
- Key Laboratory of Drug Quality Control and Pharmacovigilance; China Pharmaceutical University; 24 Tongjiaxiang Nanjing 210009 P.R. China
| | - Wenlong Huang
- Center of Drug Discovery, State Key Laboratory of Natural Medicines; China Pharmaceutical University; 24 Tongjiaxiang Nanjing 210009 P.R. China
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease; China Pharmaceutical University; 24 Tongjiaxiang Nanjing 210009 P.R. China
| | - Hai Qian
- Center of Drug Discovery, State Key Laboratory of Natural Medicines; China Pharmaceutical University; 24 Tongjiaxiang Nanjing 210009 P.R. China
- Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease; China Pharmaceutical University; 24 Tongjiaxiang Nanjing 210009 P.R. China
| |
Collapse
|
7
|
Hansen SVF, Ulven T. Pharmacological Tool Compounds for the Free Fatty Acid Receptor 4 (FFA4/GPR120). Handb Exp Pharmacol 2017; 236:33-56. [PMID: 27807695 DOI: 10.1007/164_2016_60] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
The free fatty acid receptor 4 (FFA4), also known as GPR120, is a G protein-coupled receptor that is activated by long-chain fatty acids and that has been associated with regulation of appetite, release of insulin controlling hormones, insulin sensitization, anti-inflammatory and potentially anti-obesity activity, and is progressively appearing as an attractive potential target for the treatment of metabolic dysfunctions such as obesity, type 2 diabetes and inflammatory disorders. Ongoing investigations of the pharmacological functions of FFA4 and validation of its potential as a therapeutic target depend critically on the appropriateness and quality of the available pharmacological probes or tool compounds. After a brief summary of the pharmacological functions of FFA4 and some general considerations on desirable properties for these pharmacological tool compounds, the individual compounds that have been or are currently being used as tools for probing the function of FFA4 in various in vitro and in vivo settings will be discussed and evaluated.
Collapse
Affiliation(s)
- Steffen V F Hansen
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark
| | - Trond Ulven
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark.
| |
Collapse
|
8
|
Milligan G, Shimpukade B, Ulven T, Hudson BD. Complex Pharmacology of Free Fatty Acid Receptors. Chem Rev 2016; 117:67-110. [PMID: 27299848 DOI: 10.1021/acs.chemrev.6b00056] [Citation(s) in RCA: 188] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
G protein-coupled receptors (GPCRs) are historically the most successful family of drug targets. In recent times it has become clear that the pharmacology of these receptors is far more complex than previously imagined. Understanding of the pharmacological regulation of GPCRs now extends beyond simple competitive agonism or antagonism by ligands interacting with the orthosteric binding site of the receptor to incorporate concepts of allosteric agonism, allosteric modulation, signaling bias, constitutive activity, and inverse agonism. Herein, we consider how evolving concepts of GPCR pharmacology have shaped understanding of the complex pharmacology of receptors that recognize and are activated by nonesterified or "free" fatty acids (FFAs). The FFA family of receptors is a recently deorphanized set of GPCRs, the members of which are now receiving substantial interest as novel targets for the treatment of metabolic and inflammatory diseases. Further understanding of the complex pharmacology of these receptors will be critical to unlocking their ultimate therapeutic potential.
Collapse
Affiliation(s)
- Graeme Milligan
- Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow , Glasgow G12 8QQ, Scotland, United Kingdom
| | - Bharat Shimpukade
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark , Campusvej 55, DK-5230 Odense M, Denmark
| | - Trond Ulven
- Department of Physics, Chemistry and Pharmacy, University of Southern Denmark , Campusvej 55, DK-5230 Odense M, Denmark
| | - Brian D Hudson
- Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow , Glasgow G12 8QQ, Scotland, United Kingdom
| |
Collapse
|
9
|
Li Z, Qiu Q, Geng X, Yang J, Huang W, Qian H. Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development. Expert Opin Investig Drugs 2016; 25:871-90. [PMID: 27171154 DOI: 10.1080/13543784.2016.1189530] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
INTRODUCTION The alarming prevalence of type 2 diabetes mellitus (T2DM) stimulated the exploitation of new antidiabetic drugs with extended durability and enhanced safety. In this regard, the free fatty acid receptor 1 (FFA1) and FFA4 have emerged as attractive targets in the last decade. FFA1 has prominent advantages in promoting insulin and incretin secretion while FFA4 shows great potential in incretin secretion, insulin sensitization and anti-inflammatory effects. AREA COVERED Herein, the authors focus specifically on FFA1 and FFA4 agonists in clinical trials and preclinical development. LY2922470, P11187 and SHR0534 are currently active in clinical trials while the CNX-011-67, SAR1, DS-1558 and BMS-986118 are in preclinical phase. The information for this review is retrieved from Integrity, Scifinder, Espacenet and clinicaltrials.gov databases. EXPERT OPINION Current proof-of-concept in clinical trials suggests that FFA1 agonists have a significant improvement for T2DM without the risk of hypoglycemia. However, there are still several challenging problems including the mechanism of the receptor and the efficacy and safety of the ligands.
Collapse
Affiliation(s)
- Zheng Li
- a Center of Drug Discovery, State Key Laboratory of Natural Medicines , China Pharmaceutical University , Nanjing , PR China
| | - Qianqian Qiu
- a Center of Drug Discovery, State Key Laboratory of Natural Medicines , China Pharmaceutical University , Nanjing , PR China
| | - Xinqian Geng
- b Department of Endocrinology and Metabolism , Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes , Shanghai , PR China
| | - Jianyong Yang
- a Center of Drug Discovery, State Key Laboratory of Natural Medicines , China Pharmaceutical University , Nanjing , PR China
| | - Wenlong Huang
- a Center of Drug Discovery, State Key Laboratory of Natural Medicines , China Pharmaceutical University , Nanjing , PR China.,c Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease , China Pharmaceutical University , Nanjing , PR China
| | - Hai Qian
- a Center of Drug Discovery, State Key Laboratory of Natural Medicines , China Pharmaceutical University , Nanjing , PR China.,c Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease , China Pharmaceutical University , Nanjing , PR China
| |
Collapse
|
10
|
Abstract
FFA1 is a G protein-coupled receptor activated by medium- to long-chain fatty acids. FFA1 plays important roles in various physiological processes such as insulin secretion and energy metabolism. FFA1 expressed on pancreatic β-cells and intestine contributes to insulin and incretin secretion, respectively. These physiological functions of FFA1 are interesting as an attractive drug target for type II diabetes and metabolic disorders. A number of synthetic FFA1 ligands have been developed and they have contributed to our current understanding of the physiological and pathophysiological functions of FFA1 both in in vitro and in vivo studies. In addition, these synthetic ligands also provided information on the structure-activity relationships of FFA1 ligands. Further, FFA1 protein crystallized with one of the high affinity agonist leads provided useful insights for the development of more effective ligands. Among FFA1 ligands, several compounds have been further investigated in the clinical trials. Thus, FFA1 ligands have great potential as drug candidates. In this section, recent progress about FFA1 ligands and the possibility of their clinical use are described.
Collapse
|
11
|
Kristinsson H, Bergsten P, Sargsyan E. Free fatty acid receptor 1 (FFAR1/GPR40) signaling affects insulin secretion by enhancing mitochondrial respiration during palmitate exposure. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2015; 1853:3248-57. [DOI: 10.1016/j.bbamcr.2015.09.022] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Revised: 09/04/2015] [Accepted: 09/21/2015] [Indexed: 12/23/2022]
|